Presented by presented by
Roche and Intermune CEOs share the spotlight
Jeffrey Clark - Posted: 8/29/2014
Roche CEO Severin Schwan is joined by Intermune CEO Dan Welch to discuss Roches $8.3B acquisition of Intermune in what is the largest deal for Roche since Genentech. Pirfenidone is an orally active, small molecule drug for fibrosis. Pirfenidone is ap[...]
IRS struggling with medical-device tax under Affordable Care Act
Jeffrey Clark - Posted: 8/27/2014
The medical device tax is falling short. The revenue tax on medical device sales that was passed to help fund the Affordable Care Act is only raising 75% of expected revenue.  Apparently, the shortfall is largely due to challenges at the IRS in colle[...]
Former senators tapped to lobby for Medtronic-Covidien merger
Jeffrey Clark - Posted: 8/26/2014
Medtronic has enlisted former Senators John Breaux from Louisiana and Trent Lott from Virginia to lobby for the companys pending merger with Covidien.  Public records show that Medtronic has paid the Breaux-Lott Leadership Group $200,000 to discuss b[...]
Zafgen takes different approach toward treating obesity
Jeffrey Clark - Posted: 8/22/2014
Zafgen CEO Tom Hughes discusses the companys focus on obesity with CNBC. Hughes says the new drug works to impact the way the body handles fat. Just more than two years ago, Arena Pharmaceuticals and Vivus won approval for the first new obesity drugs[...]
Forbes: Preventing A Dangerous Race To The Bottom In Biotechnology
Jeffrey Clark - Posted: 8/21/2014
In an op-ed published through, University of Chicago economist Tomas Philipson debates the effect of biosimilars in terms of naming, quality and price differentiation as they begin to enter the healthcare market.  Philipson, from the Harri[...]
Allergan approaches Salix in attempt to thwart Valeant deal
Jeffrey Clark - Posted: 8/20/2014
Allergan has approached Raleigh-based Salix Pharmaceuticals about a potential acquisition that could thwart Valeant’s hostile bid for the company. While it is unclear where the talks stand, Allergan could strike a takeover deal with Salix or another [...]
Roche acquisition rumor disavowed by Chugai
Jeffrey Clark - Posted: 8/19/2014
Yesterday, the industry was abuzz with the idea Roche was planning to buyout the 40% of Chugai Pharmaceuticals that it does not already own for almost $10B. Bloomberg, Reuters and the Wall Street Journal all reported as such. Today, a much different [...]
Regeneron CEO: How I became a billionaire
Jeffrey Clark - Posted: 8/18/2014
Regeneron CEO Leonard Schleifer shares his story with CNN, from founding the company and the journey to success to now become a billionaire.
Cool technology: Sharks hold the key to curing cancer?
Jeffrey Clark - Posted: 8/15/2014
Cool technology: Sharks hold the key to curing cancer?
Allergan v. Valeant: Update and Insight
Jeffrey Clark - Posted: 8/13/2014
The New York Times offers a much-needed update and insight into the strategy behind Allergan vs. Valeant. NY Times
Will life sciences step up to combat Ebola?
Jeffrey Clark - Posted: 8/12/2014
Every 1-2 years the life sciences industry is faced with a world health crisis.  We've seen the script play out with HIV, SARS, bird flu, mad cow disease and now Ebola. In this CNBC interview, Mount Sinai CEO Ken Davis explains how the hospital [...]
MannKind licenses inhaled insulin to Sanofi in up to $925M deal
Jeffrey Clark - Posted: 8/11/2014
MannKind has licensed its newly approved inhaled insulin product, Afrezza, to Sanofi.  Less than two months after its FDA approval, Afrezza now belongs to Sanofi for global development and commercialization with hopes it will enter the market before [...]
GSK employees convicted, jailed in China scandal
Jeffrey Clark - Posted: 8/8/2014
Two American and British GSK employees are now in jail as a result of the company’s improprieties in China. Chinese officials would not allow family or foreign diplomats to attend the trial. The husband-and-wife business partners, Peter Humphrey, a B[...]
Lilly CEO on CNBC talks acquisitions, animal healthcare
Jeffrey Clark - Posted: 8/7/2014
The big large-scale combinations are not right for Lilly right now, says John Lechleiter, Eli Lilly CEO, discussing how the company plans to expand its pharmaceutical footprint through acquiring smaller companies. Also in this interview with CNBC, Le[...]
Ranking the top 25 biotechnology companies
Jeffrey Clark - Posted: 8/6/2014
Genetic Engineering and Biotechnology News has released its list of biggest biotechnology companies, ranked by market capitalization. For sure, the industry is doing well on Wall Street with a surge in overall valuations and more than 50 new companie[...]
Experimental treatment saves US Ebola patients
Jeffrey Clark - Posted: 8/4/2014
The story reads like something out of a science fiction movie. Three top secret, experimental vials stored at subzero temperatures are flown from a US lab to western Africa in a last-ditch effort to save two American missionary workers who had contra[...]
Catalent CEO touts successful IPO
Jeffrey Clark - Posted: 8/1/2014
Catalent CEO John Chiminski discusses the companys IPO and business strategy. Catalent is a lesser known brand in the life sciences industry buy happens to be the world leader in advanced drug technologies. Catalent works with pharmaceutical companie[...]
First shots fired between Novartis, Amgen in biosimilars battle
Jeffrey Clark - Posted: 7/30/2014
The FDA has agreed to review Sandozs biologics license application for Zarzio, its biosimilar version of Amgens Neupogen.  Neupogen is one of the products that set the foundation and helped build Amgen into what it is today.  The treatment is indicat[...]
Johnson and Johnson CEO Gorsky not surprised by Medtronic, Covidien merger
Jeffrey Clark - Posted: 7/29/2014
Johnson & Johnson CEO Alex Gorsky was recently asked about his reaction to Medtronics merger with Covidien.  Calmly, he replied that J&J saw something like this coming a mile away and beat its competitors to the punch. If you think back to about thre[...]
Righting a wrong: FDA approves painkiller to counter abuse
Jeffrey Clark - Posted: 7/28/2014
The FDA wants to help drug companies avoid the abuse of their pharmaceuticals. The agency approved a new version of Oxycodone, specifically designed to abuse. The new formulation from Purdue Pharmaceuticals contains naloxone, an ingredient that negat[...]
Google partners with Novartis for smart contact lenses, to enter diabetes market
Jeffrey Clark - Posted: 7/24/2014
Novartis has announced a partnership to develop next generation contact lenses with Google, capable of constant blood glucose monitoring and enhanced vision capabilities. The agreement is among recent moves into the health care sector by technology g[...]
Other life sciences regions playing catch up to Boston
Jeffrey Clark - Posted: 7/24/2014
Massachusetts is the capital of the life sciences industry in the US. For decades, the debate has been raging, fueled by muddled rankings, biased reporting and mostly economic development dollars.  But over the past three years or so, Boston has emer[...]
Abbott CEO defends tax inversion strategy amongst life sciences firms
Jeffrey Clark - Posted: 7/22/2014
In the wake of Pfizer/AstraZeneca and AbbVie/Shire, Abbott Labs CEO Miles White sets the record straight on tax inversions in an op-ed article for the Wall Street Journal. Inversions are legal. Not abuse. Not cheating. To those spouting the histrioni[...]
Allergan sheds workforce to fend off Valeant
Jeffrey Clark - Posted: 7/21/2014
Allergan delivered its much anticipated second quarter update this morning. Questions were looming, what would the company do to fend off Valeants hostile takeover? According to the call, Allergan will cut 1,500 jobs and eliminate another 250 vacant [...]
AbbVie acquires Shire for $54B, joins tax inversion trend
Jeffrey Clark - Posted: 7/21/2014
AbbVie agreed on Friday to buy Shire for around $54 billion, in the biggest takeover deal so far this year. The combination would create one of the 50 largest companies in the world, with nearly $25 billion in annual sales and about 30,000 employees.[...]
Roche and Intermune CEOs [...]
Roche CEO Severin Schwan is joined by Intermune CEO Dan Welch to discuss Roche’s $8.3B acquisition o[...]
Zafgen takes different ap[...]
Zafgen CEO Tom Hughes discusses the company’s focus on obesity with CNBC. Hughes says the new drug w[...]
Regeneron CEO: How I beca[...]
Regeneron CEO Leonard Schleifer shares his story with CNN, from founding the company and the journey[...]
Cool technology: Sharks h[...]
Researchers Say Sharks Could Help Combat Cancer
Will life sciences step u[...]
Every 1-2 years the life sciences industry is faced with a world health crisis. We've seen the scri[...]